• Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study 

      Cunningham, Evan B; Hajarizadeh, Behzad; Dalgard, Olav; Amin, Janaki; Hellard, Margaret; Foster, Graham R; Bruggmann, Philip; Conway, Brian; Backmund, Markus; Robaeys, Geert; Swan, Tracy; Marks, Philippa S; Quiene, Sophie; Applegate, Tanya L; Weltman, Martin; Shaw, David; Dunlop, Adrian; Bruneau, Julie; Midgard, Håvard; Bourgeois, Stefan; Thurnheer, Maria Christine; Dore, Gregory J; Grebely, Jason; Shaw, Ineke; Siriragavan, Sharmila; Horschik, Tina; Sharma, Shawn; Eevers, Anita; Andreassen, Jessica; Melkeraaen, Ingunn; Widder, Nicole; Lesneuck, Kristof; Kotsoros, Barbara; Hazelwood, Susan; Holland, Rohan; Axten, David; Von Bibra, Sally; Powis, Jeff; Mason, Kate; Ryder, Stephen; Jack, Kate; Scheidegger, Claude; Huber, Christine; Ferguson, Catherine; Staehelin, Cornelia; Lacalamita, Melanie; Fragomeli, Vincenzo; Sevehon, Alison (BMC Infectious Diseases;17(1), Journal article; Peer reviewed, 2017-06-13)
      Background The aims of this analysis were to investigate treatment completion and adherence among people with ongoing injecting drug use or receiving opioid substitution therapy (OST) in a study of response-guided therapy ...
    • Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study 

      Grebely, Jason; Dalgard, Olav; Cunningham, Evan B; Hajarizadeh, Behzad; Foster, Graham R; Bruggmann, Philip; Conway, Brian; Backmund, Markus; Robaeys, Geert; Swan, Tracy; Amin, Janaki; Marks, Philippa S; Quiene, Sophie; Applegate, Tanya L; Weltman, Martin; Shaw, David; Dunlop, Adrian; Hellard, Margaret; Bruneau, Julie; Midgard, Håvard; Bourgeois, Stefan; Staehelin, Cornelia; Dore, Gregory J (International Journal of Drug Policy;47, Journal article; Peer reviewed, 2017-09)
      Background There are few data on treatment for hepatitis C virus (HCV) infection among people with ongoing injecting drug use. This study evaluated the efficacy of response-guided therapy for chronic HCV genotypes 2/3 ...
    • Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study 

      Blach, Sarah; Zeuzem, Stefan; Manns, Michael; Altraif, Ibrahim; Duberg, Ann-Sofi; Muljono, David H; Waked, Imam; Alavian, Seyed M; Lee, Mei-Hsuan; Negro, Francesco; Abaalkhail, Faisal; Abdou, Ahmed; Abdulla, Maheeba; Rached, Antoine Abou; Aho, Inka; Akarca, Ulus; Ghazzawi, Imad Al; Kaabi, Saad Al; Lawati, Faryal Al; Namaani, Khalid Al; Serkal, Youssif Al; Al-Busafi, Said A; Al-Dabal, Layla; Aleman, Soo; Alghamdi, Abdullah S; Aljumah, Abdulrahman A; Al-Romaihi, Hamad E; Andersson, Monique I; Arendt, Vic; Arkkila, Perttu; Assiri, Abdullah M; Baatarkhuu, Oidov; Bane, Abate; Ben-Ari, Ziv; Bergin, Colm; Bessone, Fernando; Bihl, Florian; Bizri, Abdul R; Blachier, Martin; Blasco, Antonio J; Mello, Carlos E Brandao; Bruggmann, Philip; Brunton, Cheryl R; Calinas, Filipe; Chan, Henry L Y; Chaudhry, Asad; Cheinquer, Hugo; Chen, Chien-Jen; Chien, Rong-Nan; Choi, Moon Seok; Christensen, Peer B; Chuang, Wan-Long; Chulanov, Vladimir; Cisneros, Laura; Clausen, Mette R; Cramp, Matthew E; Craxi, Antonio; Croes, Esther A; Dalgard, Olav (The Lancet Gastroenterology and Hepatology;2(3), Journal article; Peer reviewed, 2017-03)
      Background The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the recent launch of direct acting antiviral ...
    • Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs 

      Midgard, Håvard; Finbråten, Ane-Kristine; Malme, K.B.; Berg-Pedersen, Riikka Mari; Tanum, Lars Håkon Reiestad; Inge Christoffer, Olsen; Bjørnestad, Ronny; Dalgard, Olav (Trials;21, Article number: 524 (2020), Journal article; Peer reviewed, 2020-06-15)
      Background: Scaled-up direct-acting antiviral (DAA) treatment of hepatitis C virus (HCV) infection among people who inject drugs (PWID) is crucial to reach the World Health Organization HCV elimination targets within 2030. ...
    • Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study 

      Safreed-Harmon, Kelly; Hetherington, Kristina L.; Aleman, Soo; Alho, Hannu; Dalgard, Olav; Frisch, Tove; Gottfredsson, Magnus; Weis, Nina; Lazarus, Jeffrey V. (PloS ONE;13(1), Journal article; Peer reviewed, 2018-01-30)
      Background and aims In the Nordic countries (Denmark, Finland, Iceland, Norway, Sweden), the prevalence of chronic hepatitis C virus (HCV) infection is relatively low in the general population, but is much higher among ...
    • Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. 

      Grebely, Jason; Bruneau, Julie; Lazarus, Jeffrey; Dalgard, Olav; Bruggmann, Philip; Treloar, Carla; Hickman, Matthew; Hellard, Margaret; Roberts, Teri; Crooks, Levinia; Midgard, Håvard; Larney, Sarah; Degenhardt, Louisa; Alho, Hannu; Byrne, Jude; Dillon, John F; Feld, Jordan J; Foster, Graham; Goldberg, David E; Lloyd, Andrew R; Reimer, Jens; Robaeys, Geert; Torrens, Marta; Wright, Nat; Maremmani, Icro; Norton, Brianna L; Litwin, Alain H; Dore, Gregory J (International Journal of Drug Policy;47, Journal article; Peer reviewed, 2017-09)
      Globally, it is estimated that 71.1 million people have chronic hepatitis C virus (HCV) infection, including an estimated 7.5 million people who have recently injected drugs (PWID). There is an additional large, but ...
    • Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial 

      Grebely, Jason; Dalgard, Olav; Conway, Brian; Cunningham, Evan B.; Bruggmann, Philip; Hajarizadeh, Behzad; Amin, Janaki; Bruneau, Julie; Hellard, Margaret; Litwin, Alain H.; Marks, Phillippa; Quiene, Sophie; Siriragavan, Sharmila; Applegate, Tanya L.; Swan, Tracy; Byrne, Jude; Lacalamita, Melanie; Dunlop, Adrian; Matthews, Gail V.; Powis, Jeff; Shaw, David; Thurnheer, Maria Christine; Weltmann, Martin; Kronborg, Ian; Cooper, Curtis; Feld, Jordan J.; Fraser, Chris; Dillon, John F.; Read, Phillip; Gane, Edward; Dore, Gregory J. (The lancet Gastroenterology & hepatology;3(3), Journal article; Peer reviewed, 2018-03)
      Background Despite revised guidelines that no longer exclude people who inject drugs (PWID) from treatment for hepatitis C virus (HCV) infection, many clinicians are reluctant to treat recent PWID. This study aimed to ...
    • Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections - a Scandinavian real-life study 

      Dalgard, Olav; Weiland, Ola; Noraberg, Geir; Karlsen, Lars Normann; Heggelund, Lars; Färkkilä, Martti; Balselv, Ulla; Berlard, Erika; Øvrehus, Anne; Kjær, Mette Skalshøi; Krarup, Henrik; Røge, Birgit Thorup; Hallager, Sofie; Madsen, Lone G; Laursen, Alex Lund; Lagging, Martin; Weis, Nina (PLoS ONE;12(7), Journal article; Peer reviewed, 2017-07-13)
      Background and aims Chronic hepatitis C virus (HCV) genotype 3 infection with advanced liver disease has emerged as the most challenging to treat. We retrospectively assessed the treatment outcome of sofosbuvir (SOF) based ...